One of the most consistent side effects of testosterone replacement therapy is testicular atrophy — the gradual reduction in testicular size that occurs when the HPT axis is suppressed by exogenous testosterone. Gonadorelin is the primary tool used to prevent this. Here is what it is, how it works, and why it has become a standard addition to well-managed TRT protocols.
When exogenous testosterone is introduced, the hypothalamus detects elevated androgen levels and reduces its output of GnRH (gonadotropin-releasing hormone). The pituitary responds by reducing LH and FSH. Without LH stimulation, the Leydig cells in the testes reduce testosterone production. Without FSH, spermatogenesis (sperm production) is impaired.
The result, over months to years of TRT, is testicular atrophy — a reduction in testicular volume due to reduced function. For many men this is cosmetically significant. For men who wish to maintain fertility, it is clinically significant. It is also associated with reduced intratesticular testosterone, which some research suggests affects mood and wellbeing independently of serum testosterone levels.
Gonadorelin is a synthetic form of GnRH (gonadotropin-releasing hormone) — the hypothalamic hormone that normally triggers pituitary LH and FSH release. Administered in pulsatile fashion (as the hypothalamus naturally delivers it), it stimulates the pituitary to produce LH, which in turn stimulates the testes.
This is the key distinction from HCG (human chorionic gonadotropin), which was previously the standard approach. HCG mimics LH directly at the testicular level. Gonadorelin works upstream, stimulating the entire HPT axis including FSH production — making it more physiologically complete than HCG alone.
Gonadorelin is typically administered via SubQ injection twice daily — morning and evening — to mimic the pulsatile nature of natural GnRH release. Continuous exposure to GnRH actually downregulates GnRH receptors (which is how GnRH agonists like leuprorelin suppress testosterone in prostate cancer treatment). Pulsatile dosing is essential.
Doses vary by individual response and protocol. The goal is to maintain testicular size and function — not necessarily to restore full natural testosterone production, which TRT is already replacing.
It is worth noting that in the UK, gonadorelin is not licensed specifically for TRT maintenance, but is used off-label by private TRT clinics for this purpose. Prescribing physicians should be consulted about appropriateness.
For men on TRT who wish to conceive, the situation requires careful management. TRT suppresses spermatogenesis significantly. Men wishing to maintain fertility while on testosterone therapy require active management — typically involving gonadorelin or, for active fertility attempts, temporary cessation of TRT with gonadorelin and/or clomiphene support.
This is a complex clinical situation and one that requires specialist input from a reproductive endocrinologist or andrologist, not just a TRT prescriber.
The Gonadorelin compound entry on the platform covers mechanism, research evidence, and dosing context. The TRT Companion Protocol brings together testosterone, gonadorelin, and the peptide additions (BPC-157, GHK-Cu) used by men managing long-term TRT — with the blood work schedule that monitors all relevant markers. Both are available to platform members.
We'll email you when we publish something new. Free, no account needed, unsubscribe anytime.
Full TRT blood work calendar, gonadorelin protocol and peptide companion guide — available to members.